BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 16203964)

  • 1. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
    Bouyain S; Longo PA; Li S; Ferguson KM; Leahy DJ
    Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15024-9. PubMed ID: 16203964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
    Feroz K; Williams E; Riese DJ
    Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands.
    van der Woning SP; van Rotterdam W; Nabuurs SB; Venselaar H; Jacobs-Oomen S; Wingens M; Vriend G; Stortelers C; van Zoelen EJ
    J Biol Chem; 2006 Dec; 281(52):40033-40. PubMed ID: 17032651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single ligand is sufficient to activate EGFR dimers.
    Liu P; Cleveland TE; Bouyain S; Byrne PO; Longo PA; Leahy DJ
    Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10861-6. PubMed ID: 22699492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB Receptors and Cancer.
    Wang Z
    Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.
    Mill CP; Gettinger KL; Riese DJ
    Exp Cell Res; 2011 Feb; 317(4):392-404. PubMed ID: 21110957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.
    Garrett TP; McKern NM; Lou M; Elleman TC; Adams TE; Lovrecz GO; Kofler M; Jorissen RN; Nice EC; Burgess AW; Ward CW
    Mol Cell; 2003 Feb; 11(2):495-505. PubMed ID: 12620236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
    Cho HS; Mason K; Ramyar KX; Stanley AM; Gabelli SB; Denney DW; Leahy DJ
    Nature; 2003 Feb; 421(6924):756-60. PubMed ID: 12610629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ErbB4 extracellular region retains a tethered-like conformation in the absence of the tether.
    Liu P; Bouyain S; Eigenbrot C; Leahy DJ
    Protein Sci; 2012 Jan; 21(1):152-5. PubMed ID: 22012915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma.
    Liu S; Geng R; Lin E; Zhao P; Chen Y
    Front Genet; 2021; 12():602160. PubMed ID: 33732282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The single transmembrane domains of ErbB receptors self-associate in cell membranes.
    Mendrola JM; Berger MB; King MC; Lemmon MA
    J Biol Chem; 2002 Feb; 277(7):4704-12. PubMed ID: 11741943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand discrimination in signaling through an ErbB4 receptor homodimer.
    Sweeney C; Lai C; Riese DJ; Diamonti AJ; Cantley LC; Carraway KL
    J Biol Chem; 2000 Jun; 275(26):19803-7. PubMed ID: 10867024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
    Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
    Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
    Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
    Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression.
    Sundaresan S; Roberts PE; King KL; Sliwkowski MX; Mather JP
    Endocrinology; 1998 Dec; 139(12):4756-64. PubMed ID: 9832411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry.
    Ward MD; Leahy DJ
    J Biol Chem; 2015 Jan; 290(3):1570-9. PubMed ID: 25468910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of epidermal growth factor receptor 4 in oral leukoplakia.
    Kobayashi H; Kumagai K; Gotoh A; Eguchi T; Yamada H; Hamada Y; Suzuki S; Suzuki R
    Int J Oral Sci; 2013 Mar; 5(1):14-20. PubMed ID: 23492901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding specificities and affinities of egf domains for ErbB receptors.
    Jones JT; Akita RW; Sliwkowski MX
    FEBS Lett; 1999 Mar; 447(2-3):227-31. PubMed ID: 10214951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor.
    Alvarado D; Klein DE; Lemmon MA
    Nature; 2009 Sep; 461(7261):287-91. PubMed ID: 19718021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.